One shot: As part of the clinical trial, researchers gave participants a single dose of 3BNC117, a so-called broadly neutralizing antibody capable of fighting a wide range of HIV strains.
The development of antiretroviral therapy, a combination of drugs that slows the replication of HIV in the body, has transformed the treatment of this infection. but there are side effects, including kidney problems, decreased bone density, and gastrointestinal problems. And if a person discontinues his or her treatment, even missing a few doses, the level of the virus in the body is able to rebound quickly. So researchers are developing a new kind of treatment, an antibody-based drug that may provide a better strategy for long-term control of HIV.
Recent findings from a Phase 1 clinical trial offer new i...
Read More
Recent Comments